Compounds > cmpd 167
Page last updated: 2024-12-11

cmpd 167

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

CMPD 167: has antiviral activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5481119
CHEMBL ID3182547
MeSH IDM0458884

Synonyms (20)

Synonym
(2r)-2-[[(1r,3s,4s)-3-[[4-(5-benzyl-2-ethyl-pyrazol-3-yl)-1-piperidyl]methyl]-4-(3-fluorophenyl)cyclopentyl]-methyl-amino]-3-methyl-butanoic acid
cmpd 167
d-valine, n-[(1r,3s,4s)-3-[[4-[1-ethyl-3-(phenylmethyl)-1h-pyrazol-5-yl]-1-piperidinyl]methyl]-4-(3-fluorophenyl)cyclopentyl]-n-methyl-
mrk-1
L167 ,
mrk1
(2r)-2-[[(1r,3s,4s)-3-[[4-(5-benzyl-2-ethylpyrazol-3-yl)piperidin-1-yl]methyl]-4-(3-fluorophenyl)cyclopentyl]-methylamino]-3-methylbutanoic acid
NCGC00247944-01
dtxsid0047327 ,
cas-313994-79-5
dtxcid8027327
mk-578
tox21_300223
NCGC00254081-01
gtpl3651
(2r)-2-[[(1r,3s,4s)-3-[[4-[2-ethyl-5-(phenylmethyl)pyrazol-3-yl]piperidin-1-yl]methyl]-4-(3-fluorophenyl)cyclopentyl]-methylamino]-3-methylbutanoic acid
313994-79-5
CHEMBL3182547
Q27087736
n-((1r,3s,4s)-3-((4-(3-benzyl-1-ethyl-1h-pyrazol-5-yl)piperidin-1-yl)methyl)-4-(3-fluorophenyl)cyclopentyl)-n-methyl-d-valine

Research Excerpts

Overview

CMPD 167 is a CCR5-specific small molecule with potent antiviral activity in vitro.

ExcerptReferenceRelevance
"CMPD 167 is a CCR5-specific small molecule with potent antiviral activity in vitro."( Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection.
DeMartino, JA; Doms, RW; Dufour, J; Ketas, TJ; Klasse, PJ; Kuhmann, SE; Kunstman, K; Lifson, JD; Lyons, K; Marx, PA; Mefford, M; Moore, JP; Pandrea, I; Piatak, M; Reeves, JD; Siciliano, SJ; Springer, MS; Veazey, RS; Wolinsky, SM, 2003)		1.04
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
SMAD family member 2Homo sapiens (human)Potency22.01750.173734.304761.8120AID1346859; AID1346924
SMAD family member 3Homo sapiens (human)Potency22.01750.173734.304761.8120AID1346859; AID1346924
GLI family zinc finger 3Homo sapiens (human)Potency54.48270.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency24.00270.000221.22318,912.5098AID743035; AID743036
progesterone receptorHomo sapiens (human)Potency39.59780.000417.946075.1148AID1346784; AID1346795
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency61.64480.000214.376460.0339AID720691
retinoid X nuclear receptor alphaHomo sapiens (human)Potency20.95760.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency51.57150.001530.607315,848.9004AID1224848; AID1224849; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency23.20680.375827.485161.6524AID743217; AID743220
estrogen nuclear receptor alphaHomo sapiens (human)Potency26.31250.000229.305416,493.5996AID743069; AID743075; AID743078
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency24.54120.001024.504861.6448AID743212
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency34.04010.001019.414170.9645AID743094; AID743140; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency7.87710.023723.228263.5986AID743222; AID743223; AID743241
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency61.13060.000323.4451159.6830AID743065; AID743067
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (66.67)29.6817
2010's4 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.76

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.76 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.76)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
medroxyprogesterone acetate
[no description available]		2.071020-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
corticosteroid;
steroid ester		adjuvant;
androgen;
antineoplastic agent;
antioxidant;
female contraceptive drug;
inhibitor;
progestin;
synthetic oral contraceptive
valine
Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.. valine : A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group.. L-valine : The L-enantiomer of valine.		3.91120L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine		algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		2.74301,2,3-triazole
tak 779
[no description available]		2.0510
maraviroc
[no description available]		2.7430tropane alkaloid
vicriviroc
vicriviroc: structure in first source		2.0310(trifluoromethyl)benzenes
bms 806
BMS 806: prevents entry of HIV into cells by binding HIV envelope protein gp120; no further info available 4/2002		2.7230
peptide t1249
peptide T1249: peptide derived from HR2 segment; gp41, intertwined heptad-repeat (HR2) regions form hydrophobic grooves that fold over and bind to corresponding HR1 coiled coils, collapsing gp41 into a stable six-helix or trimer of hairpins configuration; HIV fusion inhibitor		2.0610
cyclosporine
Cyclosporine: A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed).		2.0310
ConditionIndicatedRelationship StrengthStudiesTrials
HIV Coinfection
[description not available]		03.4270
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		02.4420
HIV Infections
Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).		03.4270
AIDS, Simian
[description not available]		03.1250
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.4320
Innate Inflammatory Response
[description not available]		02.0310
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0310
Vascular Diseases
Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.		02.0310